

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was raised during scoping that there are inconsistencies between devolved nation decisions on the provision of abiraterone and that this could lead to inequalities by geographical UK region. For example, abiraterone is available in Scotland, but not in England.

It was also raised that prostate cancer is a condition that can only affect people with a prostate, and therefore men and others assigned male at birth.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Difference of approach on whether to fund treatments between devolved nations is not considered an equality issue.

Any recommendation made will be made in line with the marketing authorisation which includes all adults with prostates, including men and others assigned male at birth.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No.

Approved by Associate Director (name): Richard Diaz

Date: 25/04/2025